360
94222226014562123
Ces8507936014570127174
Urol10497936014578115180208
2023;12827936014562121178238260
27(2):15677936014562119147205235257
86-9418507936014561123163224286
PŘEHLEDOVÉ852207016974156235334409485586692777855
ČLÁNKY1754207016981154252352436525
29.850896013356110129
Malmstrom998896013388141166256298335370429520
TK,1537896013354114139
Morley1695896013388148184209263314
JE.202889601334094118
SARC‑F:2166898013151113166228247298314
A2500898013164
Simple258489801315171159218241293
Questionnaire2897898013174131184224258280337395452500522553604
to352089801313490
Rapidly3630898013155104163185244266313
Diagnose396389801317193141200257315354407
Sarcopenia.4390898013151100131177233292346403425472492
J4901898013138
Am4959898013164153
Med5132898013185137197
Dir850104801317194125
Assoc.9991048013164106146204254273
2013;12961048013154105153197213
14(8):15331048013154100129180206223
531–2.17801048013154104150199247264
30.8501196013356110131
Ohtaka10001196013375135169222271324
A,1343119601336690
Aoki14521196013367125175201
H,1672119601337193
Nagata17841196013372124184235269322
M,21241196013388111
et2254119601335490
al.236211960133537799
Sarcopenia2481119801315099130176230290342399420468
is2968119801312361
a30481198013149
poor31171198013160118176207
prognostic3343119801316091147206263320359393414461
factor3824119801312878125161216247
of4090119801315886
castrationresistant4195119801314897136170201250281302359416447497537557595629678734765
prostate4980119801316091146185219268299349
cancer850134801314999157205256287
treated1162134801313465117165197248308
with14941348013180102136194
docetaxel17121348013160118167218251301349400422
therapy.2159134801313492145176226285333346
Prostate2529134801315586142182217267299350
Int.2903134801312381113132
2019;30591348013153105153198216
7(1):3299134801315477125145162
9–14.34851348013153111157203221
31.8501496013356105122
Parkin9921496013358109144194221281
DM,12921496013373160184
Bray1495149601335994147196
F,1710149601335465
Ferlay17951496013353106141167218268
J,2082149601334061
Pisani2163149601335881124176236261
P.2443149601335868
Global2531149801316891149208258280
Cancer28311498013162111169217267298
Statistics,3149149801315182131162184223257279326368386
2002.35551498013153104159208226
CA38011498013162127
Cancer39481498013162111169217267298
J42661498013138
Clin.4324149801316284105162181
2005;45251498013153104159210224
55(2):47691498013153102127178204220
74–108.5009149801315398155201247301320
32.8501646013356108131
Ibrahim1000164601332688123176235260350
A,1370164601336691
Scher14801646013354103162217252
N,1751164601337295
Williams18651646013393119143168193244335377
G,2261164601337194
et2374164601335591
al.2484164601335378100
Approval26051648013164123183215271318368390
Summary30141648013151107196284332363414
for3448164801312985117
Zoledronic35851648013159114137189249280336394415463
Acid40681648013164111132191
for4279164801312885117
Treatment4415164801315176127174206295347405436
of4871164801315886
Multiple49771648013185142164197218277300352
Myeloma8501798013186133185208266355404
and12781798013150108167
Cancer14691798013163113171219270302
Bone17951798013155114172225
Metastases.20441798013186139172222262296346385439479498
Clin2566179801316385107164
Cancer27541798013163113170219270301
Res.30791798013156109149169
2003;32721798013153105160210226
9(7):3522179801315482134163180
2394–9.37261798013154106157211268320336
33.8501946013356110131
Katolická10041946013360114149208234259308358412
J.1439194601334162
Bisfosfonáty1526194801315678117146203243273330388437469521
u20711948013158
urologických2153194801315990146170228288310358403455502560
malignit.27371948013190139161183242300321355374
Onkologie.31351948013174133178235258316376398450468
2013:36271948013153105153197213
7(1):3864194801315477125145162
18–21.40501948013153100156203251263
34.8502096013356113135
Sharma10152096013354114167202293346
A,1391209601336792
Sinha1512209601335579139200252
RJ,17942096013359102124
Singh1947209601335579139201261
V,2238209601336177
et2345209601335591
al.2466209601335378101
Implications25982098013123112172195216264314346368426485524
of3153209801315887
the3270209801313492145
Fracture3446209801315180130178215272304355
Risk3832209801315578117162
Assessment40242098013165107147200240280368421479511
Algorithm4566209801316487146204236259292350439
for5035209801312986118
the5184209801313492145
assessment850224801315090129183223263351404462494
and13692248013150108167
improvement15622248013123111171203259308359448502559591
of2178224801315987
bone22912248013160120178231
health25472248013159112160183216274
in2846224801312381
patients29522248013160110143165217275307349
with33262248013179102135193
prostate3544224801316193150190224274306357
cancer:3926224801314999157205256287307
a42582248013150
comprehensive43342248013149105194254286337395448506546567616668
review.5027224801313384133156208287302
Türk8502398013151107138184
Ürol10582398013169100157180
DergisiTurkish12622398013171125156214236275296349399430476500539597
J18832398013138
Urol.19452398013169100156179197
2019;21672398013153105153198216
45(4):24072398013154103129178203220
245–53.26512398013154102151206258307325
35.8502546013356110130
Shahinian10042546013354114167227252312337389450
VB,14772546013362122144
Goodwin16442546013372133193256337362422
JS.2090254601334194116
Risk2231254801315678117162
of2417254801315987
Fracture2528254801315180130179215272304355
after2907254801315078116167198
Androgen31292548013165123182214270330383441
Deprivation35942548013172125185217240289339371393451509
for4127254801312986118
Prostate4270254801315585142182216266298349
Cancer.46432548013163113170219270301315
N49832548013170
Engl50772548013151109168190
J52912548013138
Med.8502698013186139199218
2005;10922698013154105160212227
352(2):13432698013153103153178229256272
154–64.1639269801315499152209266322339
36.8502846013356112134
Oefelein10112846013376132164219245300326386
MG,14242846013388159183
Ricchiuti1634284601335985134181241266326362387
V,2048284601336177
Conrad21522846013364123183219271333
W,25122846013393111
Resnick26502846013359114157217242291342
MI.30192846013388115138
Skeletal3185284801315196148170223256306328
fractures3541284801312962112160197254285337377
negatively39462848013159112173221253276325377399447
correlate44212848013149105137169221243292324375
with48242848013180102135194
overall50452848013159107159190240263284
survival850299801314197129182205254304326
in1200299801312380
men13052998013190143201
with15302998013179102135193
prostate1747299801316193149189224274306357
cancer.2128299801314999156205256287301
The24532998013152112165
Journal2642299801313896154185244293315
of2981299801315987
Urology.30922998013169100156179237298346360
2002;34762998013153105160210227
168(3):37272998013154100154182233258275
1005–1007.40262998013153100155207262308356411460467
37.8503146013356109120
Sweeney9903146013355133187243304359410
CJ,14203146013364107128
Chen15693146013364123178239
YH,18293146013359131154
Carducci20043146013364117152213273322369394
M,24193146013388112
et2552314601335591
al.2664314601335378101
Chemohormonal27863148013163120173262321379437469559618676725747
Therapy35553148013151111164195245305352
in3928314801312381
Metastatic40303148013185139172221261296345377399448
Hormone‑Sensitive44993148013169128160250308366419454501555612652673706729778830
Prostate850329801315586142182217266299350
Cancer.12243298013162112170218269301315
N15633298013170
Engl16573298013151109168190
J18713298013138
Med.19333298013186139199218
2015;21753298013154105153198213
373(8):24123298013153102153180231257274
737–46.27103298013153105153202258313332
38.8503446013356112135
Kyriakopoulos10093446013360107143169221272330393454514539600642
CE,16763446013363116139
Chen18393446013364124179239
YH,21033446013359131154
Carducci22823446013363116151213273322369394
MA,27003446013389156181
et2905344601335591
al.3021344601335378100
Chemohormonal31473448013163120173262321379438470560618676725747
Therapy39193448013152112165196246305353
in4297344801312380
Metastatic44023448013186139172222262296346378400448
Hormone­48753448013170128160250308367420454
‑Sensitive850359801313380134192231253286308358410
Prostate1292359801315686143183218268300351
Cancer:16763598013163112170219270302322
Long‑Term20303598013150107165225258303349381471
Survival25333598013152108140193216265315338
Analysis29033598013165123172194242283305344
of3279359801315987
the3399359801313492145
Randomized35773598013155105163223281371393437489549
Phase41593598013155112161201254
III444635980131234567
E380545453598013152106158212264
CHAARTED48413598013163131194260315367419488
Trial.85037480131517698147169187
J10613748013138
Clin1123374801316385106164
Oncol.13113748013174133181237260279
2018;16143748013154105153199216
36(11):18543748013154106134182222243259
1080–7.21373748013154101155209267314321
39.8503896013356110129
Gravis10033896013371108160211237279
G,1307389601337195
Boher14263896013360120181236272
JM,17233896013340128152
Chen19003896013363123178239
YH,21633896013360132155
et2342389601335692
al.2458389601335379101
Burden25853898013156113144202255313
of2923389801315987
Metastatic30363898013185138172221261295345377399448
Castrate35093898013163112152187218268300351
Naive38863898013170119141190242
Prostate4153389801315586142182217266298349
Cancer45283898013162112170219269301
Patients,48543898013155103135158210268300342360
to5239389801313490
Identify850404801312381133190221242269321
Men11904048013184137193
More14034048013184141172223
Likely1645404801314970114165187234
to1898404801313388
Benefit20054048013155108164216241267300
from2324404801312860116204
Early2547404801315199130152199
Docetaxel:27654048013170128177226258307354404426442
Further32264048013151104135171228280310
Analyses35554048013164121169190237276328368
of3942404801315885
CHAARTED40474048013161128189254307357408476
and45434048013149105164
GETUG‑AFU1547264048013168117169238304337399448513559603
Studies.850419801315182140199221274314333
Eur12084198013151106137
Urol.13694198013169100157180198
2018;15914198013154105153200217
73(6):18324198013153105132182208225
847–20814198013154109157206
55.23114198013154102119
40.8504346013356114136
Fizazi1008434601335478124179226251
K,1282434601335985
Tran1389434601335584137197
N,1608434601337396
Fein17264346013354107133193
L,1941434601335276
et2039434601335591
al.2153434601335378101
Abiraterone22774348013164124147178228260311343399458511
plus2811434801316084140180
Prednisone3014434801315586137197255277316374432486
in3523434801312380
Metastatic,36264348013186139172222261296346378400448467
Castration41164348013162112152186218268300322380438
Sensitive45784348013151104162201222256278327379
Prostate4980434801315585142182217266298349
Cancer.8504498013163112170219270301315
N11894498013170
Engl12844498013151108168190
J14984498013138
Med.15604498013185139199218
2017;18024498013153105153196209
377(4):20354498013154102155178228253270
352–60.23294498013153103153205262316334
41.8504646013356105122
Francini999464601335486139200249273334359
E,1384464601335477
Gray14884646013371107160209
KP,17244646013360119128
Xie1879464601336388142
W,20484646013393111
et2185464601335592
al.2303464601335379101
Time2432464801315176165218
of2677464801315987
metastatic27924648013190143176226265300350382404452
disease3272464801315981120173221261314
presentation3614464801316092144184237295327377409431488547
and41894648013149107167
volume43834648013150107130187276329
of4740464801315886
disease4854464801316082121174222261315
are5196464801315081133
prognostic850479801316193149210267326366400422470
for1343479801312986118
metastatic14844798013190143176226265300350382404452
hormone19594798013159117149239297356409
sensitive2390479801314295152192213246269318370
prostate2782479801316193150190224274306357
cancer3161479801315099157206257288
(mHSPC).34724798013129115183232285346377392
The38864798013151111164
Prostate.4073479801315586142182217266299350367
2018;44624798013154106153200217
78(12):47024798013153104132179224250266
889–95.49914798013154108159217269321338